Figure S8 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors

Martina S.J. McDermott; Neil A. O’Brien; Benjamin Hoffstrom; Ke Wei Gong; Ming Lu; Jun Zhang; Tong Luo; Min Liang; Weiping Jia; Jenny J. Hong; Kevin Chau; Simon Davenport; Bin Xie; Michael F. Press; Richard Panayiotou; Abram Handly‐Santana; Joan S. Brugge; Leonard Presta; John A. Glaspy; Dennis J. Slamon

doi:10.1158/1078-0432.27030343.v1

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Supplemental Figure S8. A. Layout of tissues and B. Scanned whole-slide image of BN1021, normal human tissue microarray stained for CLDN6 expression showing no staining.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

McDermott et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522d8e https://doi.org/10.1158/1078-0432.27030343.v1

View at Publisher

Ask AI

Bookmark

Share

Figure S8 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors

Ask about this paper

Abstract

Discussion

Cite This Study

Figure S8 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading